Minerva Neurosciences Corp - NERV EV/EBITDA Multiple
Minerva Neurosciences (NERV) remains stagnant due to certification hurdles while awaiting FDA confirmation of roluperidone's efficacy. The company's revenue streams depend on launching this schizophrenia therapy in the US market. This price action chart with the 0.00 metric bridges these expectations with a reality where bankruptcy risk is rising due to capital shortages and potential further regulatory rejections.
Metric breakdowns and analytics for minervaneurosciences.com (NERV)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Minerva Neurosciences|NERV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Minerva Neurosciences, Inc.|NERV - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Minerva|NERV - Company Long-Term Indebtedness|Company Short-Term Debts Minerva Neurosciences|Quick Liquidity Indicator minervaneurosciences.com
- business earnings and investment ratios data:
NERV - Net Profit|Expected Profit Minerva Neurosciences|NERV - Company Value to Net Income|Future Price to Earnings Minerva Neurosciences|NERV - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Minerva|NERV - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Minerva Neurosciences|NERV - Net earnings per share for the last 12 months|Quarterly EPS earnings growth minervaneurosciences.com|NERV - Expected net earnings per share growth this year|Earnings growth forecast for next year Minerva Neurosciences
Summary company analysis:NERV (Minerva Neurosciences Corp)
Debt load control is critical for Minerva Neurosciences (NERV), a biopharmaceutical sector player burdened by FDA rejection risks and liquidity shortages. By analyzing the business valuation via EV/EBITDA, an investor observes the ratio of the company's total enterprise value to its earnings before interest, taxes, depreciation, and amortization, which allows for an assessment of the issuer's ability to service its obligations amidst high asset volatility.
Competitor analysis for Minerva Neurosciences
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio VKTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SUPN|EV/EBITDA Multiple CPRX|EV/EBITDA Multiple denalitherapeutics.com (DNLI)|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI (Trevi Corp) - Enterprise Value to Operating Income Before Depreciation|PRAX: EV/EBITDA Multiple|Company Value to EBITDA anavex.com (AVXL)|Enterprise Value to EBITDA Ratio CBLL|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX (Annexon Biosciences Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|neurogene.com (NGNE) - Company Value to EBITDA|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|ASRT: Enterprise Value to Operating Income Before Depreciation|Coya - EV/EBITDA Multiple|Vistagen Therapeutics (VTGN) - Enterprise Value to EBITDA Ratio|OVID: EV/EBITDA Multiple|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|pepgen.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple JUNS (Jupiter Neurosciences)|Relmada Therapeutics Inc (RLMD) - Company Value to EBITDA|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation GRCE (Grace Therapeutics, Inc.)|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|KLTO (Klotho Neurosciences) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Enterprise Value to Operating Income Before Depreciation RVPH (Reviva Pharmaceuticals Holdings Inc.)|EV/EBITDA Multiple MTVA|NRXS - Company Value to EBITDA|Helius Medical Technologies - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Passage Bio Inc. PASG|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Alzamend Neuro (ALZN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to EBITDA Ratio Protagenic (PTIX)|EV/EBITDA Multiple KTTA|Total Company Value to Operating Income Before Depreciation Ratio cortigent.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI: Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio LBPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MRNS|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|WENA: EV/EBITDA Multiple|Company Value to EBITDA cerevel.com (CERE)
